Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 17, 2007. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
There are no material changes to financial performance reported in this filing. The only reported activity is an increase in Ordinary Share ADR holdings by specific individuals following the re-investment of dividends paid on April 12, 2007.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It strictly details compliance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b) regarding director transactions.
Key Facts for Investor Verification
- Transaction Date: April 16, 2007 (notification date) regarding dividend re-investment from April 12, 2007.
- Share Price: $56.84 per ADR.
- Participants: Dr. JP Garnier (712.15 ADRs), Mr. D J Phelan (152.60 ADRs), and Mr. D M Stout (73.90 ADRs).
- Plan Type: GlaxoSmithKline Performance Share Plan.